Skip to main content
. 2017 May 12;7:175. doi: 10.3389/fcimb.2017.00175

Figure 6.

Figure 6

End-point titers of anti-DV1 antibodies and protect immunity elicited by the pVAX1-D1ME under different times of vaccination (n = 6). (A) End-point titers of anti-DV1 antibodies. (B) Pathological symptoms recorded as the mean sign scores. (C) Body weight calculated as percentages compared with day 0. *p < 0.05, **p < 0.01.